nilutamide has been researched along with Adenocarcinoma in 13 studies
Adenocarcinoma: A malignant epithelial tumor with a glandular organization.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We report the case of a 69-year-old patient treated for stage C adenocarcinoma of the prostate with the combination of the luteinizing hormone-releasing hormone agonist [D-Trp6, des-Gly-NH2(10)] LHRH ethylamide and the antiandrogen nilutamide (Anandron) who developed simultaneous liver and lung toxicity." | 3.68 | Simultaneous liver and lung toxicity related to the nonsteroidal antiandrogen nilutamide (Anandron): a case report. ( Cusan, L; Dupont, A; Gomez, JL; Labrie, F; Tremblay, M, 1992) |
| "Unfortunately, every treatment for prostate cancer has adverse effects with negative impact in health-related quality of life." | 2.42 | Monotherapy in advanced prostate cancer: an overview. ( Baltogiannis, D; Charalabopoulos, K; Giannakopoulos, X; Sofikitis, N, 2004) |
| "in 1941, hormonal treatment of advanced prostatic cancer has been directed primarily at neutralizing testicular androgens by orchiectomy or estrogen therapy." | 1.27 | [Combined anti-androgen treatment in adenocarcinoma of the prostate: first use of a new therapeutically efficacious principle in hormone-dependent cancer]. ( Bélanger, A; Dupont, A; Labrie, F; Lacourcière, Y; Monfette, G; Monfette, JE, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (38.46) | 18.7374 |
| 1990's | 6 (46.15) | 18.2507 |
| 2000's | 2 (15.38) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baltogiannis, D | 1 |
| Giannakopoulos, X | 1 |
| Charalabopoulos, K | 1 |
| Sofikitis, N | 1 |
| Sartor, AO | 1 |
| Tangen, CM | 1 |
| Hussain, MH | 1 |
| Eisenberger, MA | 1 |
| Parab, M | 1 |
| Fontana, JA | 1 |
| Chapman, RA | 1 |
| Mills, GM | 1 |
| Raghavan, D | 1 |
| Crawford, ED | 1 |
| Labrie, F | 5 |
| Dupont, A | 5 |
| Bélanger, A | 4 |
| Emond, J | 1 |
| Monfette, G | 3 |
| Cusan, L | 2 |
| Lacourciere, Y | 2 |
| Laberge, JG | 1 |
| Emond, JP | 1 |
| Fazekas, AT | 1 |
| Raynaud, JP | 1 |
| Husson, JM | 1 |
| Pescatore, P | 1 |
| Hammel, P | 1 |
| Durand, F | 1 |
| Bertheau, P | 1 |
| Bernuau, J | 1 |
| Huc, D | 1 |
| Gerbal, JL | 1 |
| Degott, C | 1 |
| Benhamou, JP | 1 |
| Barthélémy, Y | 1 |
| Colombel, M | 1 |
| Gasman, D | 1 |
| Patard, JJ | 1 |
| Chopin, D | 1 |
| Abbou, CC | 2 |
| Lucas, C | 1 |
| Leblanc, V | 1 |
| Wieder, JA | 1 |
| Soloway, MS | 1 |
| Crook, JM | 1 |
| Szumacher, E | 1 |
| Malone, S | 1 |
| Huan, S | 1 |
| Segal, R | 1 |
| Gomez, JL | 1 |
| Tremblay, M | 2 |
| Monfette, JE | 1 |
| Moorjani, S | 1 |
| Lupien, PJ | 1 |
| Brun, D | 1 |
| Gagné, C | 1 |
| Giguère, M | 1 |
| Seigneur, J | 1 |
| Trechot, PF | 1 |
| Hubert, J | 1 |
| Lamy, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Trial of Enzalutamide in Combination With PSA-TRICOM in Patients With Non-Metastatic Castration Sensitive Prostate Cancer[NCT01875250] | Phase 2 | 38 participants (Actual) | Interventional | 2013-07-22 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Normal testosterone is 270-1070 nd/dL. (NCT01875250)
Timeframe: 84 days
| Intervention | ng/dl (Median) |
|---|---|
| All Participants | 834 |
Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT01875250)
Timeframe: Date treatment consent signed to date off study, approximately 43 months and 13 days for Arm A, and 78 months and 6 days for Arm B.
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm A - Enzalutamide for 3 Months | 19 |
| Arm B - Enzalutamide for 3 Months + PSA-TRICOM | 19 |
Median PSA change would be considered optimal. (NCT01875250)
Timeframe: 84 days
| Intervention | Percent change (Median) |
|---|---|
| Arm A - Enzalutamide for 3 Months | -99 |
| Arm B - Enzalutamide for 3 Months + PSA-TRICOM | -99 |
Growth rate was measured using the growth rate equation -f(t) = exp (-d*t) + exp (g*t) -1 where exp is the base of the natural algorithm, e = 2.7182 and t is days since treatment started. The tumor growth rate equation measures Prostate Specific Antigen (PSA) rise over time. The UOM is unitless because this is a way to measure PSA kinetics. (NCT01875250)
Timeframe: 7 months
| Intervention | unitless (Number) |
|---|---|
| Arm A - Enzalutamide for 3 Months | 0.031 |
| Arm B - Enzalutamide for 3 Months + PSA-TRICOM | 0.030 |
VEGF was measured by the enzyme-linked immunosorbent assay (ELISA) assay. The lower limit of quantitation of assay was 9.0 pg/ml. (NCT01875250)
Timeframe: 30 Days After the Start of Course 1 and Course 2 of Enzalutamide
| Intervention | pg/ml (Mean) | |
|---|---|---|
| Course 1 | Course 2 | |
| All Participants | 192 | 165.04 |
PSA recovery is defined as the return above baseline PSA in participants with normal testosterone and non-metastatic, castration sensitive prostate cancer. (NCT01875250)
Timeframe: up to 41 months
| Intervention | Days (Median) | |
|---|---|---|
| Course 1 | Course 2 | |
| All Participants | 224 | 189 |
1 review available for nilutamide and Adenocarcinoma
| Article | Year |
|---|---|
Monotherapy in advanced prostate cancer: an overview.
Topics: Adenocarcinoma; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Combined Modality T | 2004 |
3 trials available for nilutamide and Adenocarcinoma
| Article | Year |
|---|---|
Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426).
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Bone Neoplasms; Disease-Fre | 2008 |
[Tolerance and clinical and biological responses during the first 6 months of treatment with 1-month sustained release LHRH agonists leuprolerin and triptolerin in patients with metastatic prostate cancer].
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents; Antineoplastic | 1997 |
Intermittent androgen suppression in the management of prostate cancer.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Follow-Up Stud | 1999 |
9 other studies available for nilutamide and Adenocarcinoma
| Article | Year |
|---|---|
Simultaneous administration of pure antiandrogens, a combination necessary for the use of luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer.
Topics: Acid Phosphatase; Adenocarcinoma; Androgen Antagonists; Buserelin; Drug Therapy, Combination; Humans | 1984 |
New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen.
Topics: Adenocarcinoma; Androgen Antagonists; Animals; Bone Neoplasms; Buserelin; Drug Therapy, Combination; | 1982 |
[Fatal fulminant hepatitis induced by nilutamide (Anandron)].
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Chemical and Drug Induced Liver Injury; Drug Interaction | 1993 |
[Antiandrogen withdrawal syndrome in the hormonal treatment of metastatic prostatic cancer in hormonal escape].
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Chemotherapy, Adjuvant; | 1996 |
Interstitial pneumonitis associated with neoadjuvant leuprolide and nilutamide for prostate cancer.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined | 1998 |
Simultaneous liver and lung toxicity related to the nonsteroidal antiandrogen nilutamide (Anandron): a case report.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Agents; Antineoplastic Combined Chemother | 1992 |
[Combined anti-androgen treatment in adenocarcinoma of the prostate: first use of a new therapeutically efficacious principle in hormone-dependent cancer].
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Agents; Drug Therapy, Combination; Flutam | 1986 |
Increase in plasma high-density lipoprotein concentration following complete androgen blockage in men with prostatic carcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Androgens; Antineoplastic Combined Ch | 1987 |
Pulmonary complications of hormone treatment in prostate carcinoma.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Buserelin; Drug Therapy, Combination; Humans; Imidazoles | 1988 |